FDA Grants Breakthrough Therapy Designation to Sacituzumab Govitecan for Second-Line ES-SCLC
Sacituzumab govitecan has received FDA breakthrough therapy designation for patients with extensive-stage small cell lung cancer in the second line.
Related Articles
FDA Approves Remestemcel-L for Pediatric Steroid-Refractory Acute Graft-vs-Host Disease
The FDA has approved remestemcel-L-rknd for pediatric steroid-refractory acute graft-vs-host disease.
FDA Approves Ensartinib for Locally Advanced or Metastatic ALK+ NSCLC
The FDA has approved ensartinib for patients with ALK+ locally advanced or metastatic NSCLC who have not previously received an ALK inhibitor.
Call-for-Papers | JACC: CardioOncology
Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…
Consolidation Durvalumab Improves PFS in Unresectable Stage III NSCLC Without Progression After CRT
The PACIFIC-5 study has met its primary end point of improved PFS with consolidation durvalumab after CRT in select unresectable stage III NSCLC.
Johnson & Johnson Seeks EMA Approval for Ibrutinib Plus R-CHOP in Frontline MCL
Johnson & Johnson has submitted a type II variation application to the EMA seeking the approval of ibrutinib plus R-CHOP in ASCT-eligible frontline MCL.
Menin Inhibitor–Based Combinations Are Central to Ongoing Research in KMT2A+/NPM1+ AML
Maximilian Stahl, MD, discusses unmet needs in relapsed/refractory AML, highlighting the potential utility menin inhibitors in select populations.
Long-Term Data Support Continued Use of Brexu-Cel in R/R Mantle Cell Lymphoma
Long-term data from ZUMA-2 displayed durable responses with brexu-cel in relapsed/refractory mantle cell lymphoma.
Alternate definitions of adverse pathology to predict a very high risk of metastasis in men with intermediate‐ and low‐risk prostate cancer
Although different adverse pathology definitions predict a higher risk of biochemical recurrence, metastasis, castrate-resistant prostate cancer, and prostate cancer–specific mortality, the absolute …
An Introduction to Front-line Nivolumab/Ipilimumab Therapy for uHCC: The CheckMate 9DW Study.
James J. Harding, MD, reviews the ongoing phase 3 CheckMate 9DW trial, which is investigating nivolumab plus ipilimumab (NIVO + IPI) vs lenvatinib or sorafenib…
Gender equity in oncology: Progress, challenges, and the path forward in urologic oncology and oncologic specialties
Despite the increasing number of women in medicine, gender disparities in leadership and career advancement, particularly in oncology, remain prominent. Addressing issues such as pay…